Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030.
Graduate Program in Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, Houston, Texas 77030.
J Biol Chem. 2019 Dec 13;294(50):19279-19291. doi: 10.1074/jbc.RA119.008068. Epub 2019 Nov 1.
The D2 dopamine receptor and the serotonin 5-hydroxytryptamine 2A receptor (5-HT2A) are closely-related G-protein-coupled receptors (GPCRs) from the class A bioamine subfamily. Despite structural similarity, they respond to distinct ligands through distinct downstream pathways, whose dysregulation is linked to depression, bipolar disorder, addiction, and psychosis. They are important drug targets, and it is important to understand how their bias toward G-protein β-arrestin signaling pathways is regulated. Previously, evolution-based computational approaches, difference Evolutionary Trace and Evolutionary Trace-Mutual information (ET-Mip), revealed residues and residue pairs that, when switched in the D2 receptor to the corresponding residues from 5-HT2A, altered ligand potency and G-protein activation efficiency. We have tested these residue swaps for their ability to trigger recruitment of β-arrestin2 in response to dopamine or serotonin. The results reveal that the selected residues modulate agonist potency, maximal efficacy, and constitutive activity of β-arrestin2 recruitment. Whereas dopamine potency for most variants was similar to that for WT and lower than for G-protein activation, potency in β-arrestin2 recruitment for N124H was more than 5-fold higher. T205M displayed high constitutive activity, enhanced dopamine potency, and enhanced efficacy in β-arrestin2 recruitment relative to WT, and L379F was virtually inactive. These striking differences from WT activity were largely reversed by a compensating mutation (T205M/L379F) at residues previously identified by ET-Mip as functionally coupled. The observation that the signs and relative magnitudes of the effects of mutations in several cases are at odds with their effects on G-protein activation suggests that they also modulate signaling bias.
D2 多巴胺受体和 5-羟色胺 5-羟色胺 2A 受体(5-HT2A)是密切相关的 G 蛋白偶联受体(GPCR),来自 A 类生物胺亚家族。尽管结构相似,但它们通过不同的下游途径对不同的配体作出反应,其失调与抑郁症、双相情感障碍、成瘾和精神病有关。它们是重要的药物靶点,了解它们对 G 蛋白 β-arrestin 信号通路的偏向性如何调节非常重要。以前,基于进化的计算方法,差异进化轨迹和进化轨迹-互信息(ET-Mip),揭示了残基和残基对,当它们在 D2 受体中被 5-HT2A 的相应残基取代时,改变了配体的效力和 G 蛋白的激活效率。我们已经测试了这些残基替换在多巴胺或血清素刺激下触发β-arrestin2 募集的能力。结果表明,选定的残基调节激动剂的效力、最大功效和β-arrestin2 募集的组成活性。虽然大多数变体的多巴胺效力与 WT 相似且低于 G 蛋白激活,但 N124H 的效力高于 5 倍以上。T205M 显示出高组成活性、增强的多巴胺效力和增强的β-arrestin2 募集功效,与 WT 相比,而 L379F 几乎没有活性。这些与 WT 活性的显著差异在很大程度上被 ET-Mip 先前鉴定为功能耦合的残基的补偿性突变(T205M/L379F)所逆转。观察到在几种情况下,突变的作用的符号和相对大小与它们对 G 蛋白激活的作用不一致,这表明它们也调节信号偏向性。